Westlake Pharmaceuticals was founded in Hangzhou in September 2020. Building on the research foundations of Westlake University and Westlake Laboratory, we put cell biology, structural biology, medicinal chemistry and artificial intelligence on the same bench, and discover original medicines for major human diseases.
We focus on small-molecule targeted therapies for viral and oncological diseases. Our first Class 1 innovative drug, Mprosevir® (iscartrelvir hydrochloride tablets), was approved in July 2026 — the first approved drug worldwide to originate from DEL screening, with artificial intelligence deeply involved in its discovery.
Our companyA DNA-encoded library screens hundreds of millions of molecules at once, but the noise is overwhelming — no approved drug had come from it in 34 years. We let AI take over the noise and converge to one.
01
DEL compound library
each molecule carries a unique DNA barcode
02
1 × 10²
initial DEL hits
molecules binding to the target protein
03
9
AI-converged candidates
false positives removed in days
04
1
selected candidate
WLU6937 → Mprosevir®
Reprinted from Science and Technology Daily. The innovative drug iscartrelvir hydrochloride tablets (trade name Mprosevir®), jointly developed by Westlake University, Westlake Laboratory and Westlake Pharmaceuticals (Hangzhou) Co., Ltd., has received conditional approval from the NMPA.
Read moreOur R&D team is led by leading life-science scientists: more than 75% graduated from key universities in China and abroad, and more than 90% hold a postgraduate degree. Roles in research, medicinal chemistry and AI-driven drug design are open.
Open positions
